Carmustine injection
Products billed under this code include Bicnu, Carmustine.
Payment limit per 100 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Bicnu, Carmustine.
Payment limit per 100 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Bicnu | Heritage Pharmaceuticals Inc. | 23155-0261-41 | 1 | $195.73 |
| Carmustine | Sandoz Inc. | 00781-3474-32 | 1 | $195.73 |
| Carmustine | Heritage Pharmaceuticals Inc. | 23155-0649-41 | 1 | $195.73 |
| Carmustine | Heritage Pharmaceuticals Inc. | 23155-0790-41 | 1 | $195.73 |
| Carmustine | Dr. Reddy's Laboratories Inc. | 43598-0628-57 | 1 | $195.73 |
| Carmustine | Alembic Pharmaceuticals Inc. | 62332-0659-02 | 1 | $195.73 |
| Carmustine | Amneal Pharmaceuticals, LLC | 70121-1482-02 | 1 | $195.73 |
| Carmustine | Zydus Pharmaceuticals (USA) Inc. | 70710-1525-09 | 1 | $195.73 |
| Carmustine | Athenex Pharmaceutical Division, LLC | 70860-0223-61 | 1 | $195.73 |
| Carmustine | Meitheal Pharmaceuticals Inc. | 71288-0126-90 | 1 | $195.73 |
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Carmustine | Novadoz Pharmaceuticals LLC | 72205-0198-01 | 1 | $195.73 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $195.73 | −$44.281 | 100 MG | Carmustine injection | v1, posted September 17, 2026 |
| 3Q26 | $240.011 | −$1.792 | 100 MG | Carmustine injection | v1, posted September 15, 2026 |
| 2Q26 | $241.803 | +$9.18 | 100 MG | Carmustine injection | v1, posted September 15, 2026 |
| 1Q26 | $232.623 | −$5.833 | 100 MG | Carmustine injection | v1, posted September 15, 2026 |
| 4Q25 | $238.456 | +$64.813 | 100 MG | Carmustine injection | v1, posted September 8, 2026 |
| 3Q25 | $173.643 | +$28.046 | 100 MG | Carmustine injection | v1, posted March 10, 2026 |
| 2Q25 | $145.597 | −$109.723 | 100 MG | Carmustine injection | v1, posted March 10, 2026 |
| 1Q25 | $255.32 | −$75.551 | 100 MG | Carmustine injection | v1, posted December 19, 2025 |
| 4Q24 | $330.871 | −$47.311 | 100 MG | Carmustine injection | v1, posted June 11, 2025 |
| 3Q24 | $378.182 | +$97.262 | 100 MG | Carmustine injection | v1, posted June 11, 2025 |
| 2Q24 | $280.92 | +$9.455 | 100 MG | Carmustine injection | v1, posted March 11, 2025 |
| 1Q24 | $271.465 | −$138.238 | 100 MG | Carmustine injection | v1, posted December 19, 2024 |
| 4Q23 | $409.703 | −$1.259 | 100 MG | Carmustine injection | v1, posted October 10, 2024 |
| 3Q23 | $410.962 | +$106.343 | 100 MG | Carmustine injection | v1, posted June 5, 2024 |
| 2Q23 | $304.619 | +$58.658 | 100 MG | Carmustine injection | v1, posted February 23, 2024 |
| 1Q23 | $245.961 | −$222.071 | 100 MG | Carmustine injection | v1, posted December 6, 2023 |
| 4Q22 | $468.032 | −$292.794 | 100 MG | Carmustine injection | v1, posted June 22, 2023 |
| 3Q22 | $760.826 | −$40.269 | 100 MG | Carmustine injection | v1, posted June 9, 2023 |
| 2Q22 | $801.095 | −$298.727 | 100 MG | Carmustine injection | v1, posted December 14, 2022 |
| 1Q22 | $1,099.822 | −$134.635 | 100 MG | Carmustine injection | v1, posted June 8, 2022 |
| 4Q21 | $1,234.457 | −$487.566 | 100 MG | Carmustine injection | v1, posted June 2, 2022 |
| 3Q21 | $1,722.023 | −$2.341 | 100 MG | Carmustine injection | v1, posted June 2, 2022 |
| 2Q21 | $1,724.364 | −$18.881 | 100 MG | Carmustine injection | v1, posted March 1, 2022 |
| 1Q21 | $1,743.245 | – | 100 MG | Carmustine injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.